{"prompt": "['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Synopsis Primary endpoints and Section 9.1.1 Primary endpoint', 'Occurrence of potential bacterial and viral pathogens in sputum of stable COPD', 'patients and during AECOPD, over the course of 1 year:', '-', 'Bacterial pathogens, as identified by bacteriological methods, including (but not', 'necessarily limited to) H. influenzae, M. catarrhalis, S. pneumoniae, S. aureus,', 'P. aeruginosa, K. pneumoniae and A. baumannii.', 'Viral pathogens, as identified by RT PCR, including (but not necessarily limited', 'to) RSV, parainfluenza virus, enterovirus/ Human Rhinovirus (HRV),', 'metapneumovirus, influenza virus, adenovirus, bocavirus and coronavirus-and', 'by HRV quantitative RT PCR.', 'Section 7.1.1 Definition of an adverse event', 'An AE is any untoward medical occurrence in a subject, temporally associated with the', 'use of a medicinal product, whether or not considered related to the medicinal product, or', 'temporally associated with a study procedure.', 'Examples of an AE include', 'Signs, symptoms, or the clinical sequelae of a suspected interaction.', 'Examples of an AE DO NOT include:', 'Medical or surgical procedures (e.g., endoscopy, appendectomy); the condition that', 'leads to the procedure is an AE.', 'Situations where an untoward medical occurrence did not occur (e.g., social and/or', 'convenience admission to a hospital, admission for routine examination).', 'Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present', 'or detected at the start of the study that do not worsen.', 'Occurrence of a severe AECOPD, unless in the opinion of the Investigator this is', 'related to study procedure.', '19-OCT-2018', '118', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Section 7.2.1 Time periods for detecting and recording AEs and SAEs - Table 10', 'Study activity', 'Screening', 'Visit 1', 'Visit 2', 'Visit 3', 'AECOPD', 'Study', 'Visit', 'Visit', 'Conclusion', 'Pre-Month', 'M 0', 'M 6', 'M 12', 'Within 96', '0', 'hours of', 'onset', 'symptoms', 'AEs/SAEs', 'related to', 'study', 'participation*', 'AEs/SAEs', 'leading to', 'withdrawal', 'from the', 'study', 'Section 7.2.2.1 Active questioning to detect SAEs', 'Each subject/ will be instructed to contact the investigator immediately should the subject', 'manifest any signs and symptoms (s)he perceives/ they perceive as serious. However, an', 'occurrence of severe AECOPD is not defined as an SAE and therefore does not need to', 'be reported as such, unless in the opinion of the Investigator this is related to a study', 'procedure.', 'Appendix A', 'Table 15 Outsourced Laboratories', 'Laboratory', 'Address', 'Q\u00b2 Solutions Clinical Trials (US)', '27027 Tourney Road, Suite 2E', 'Valencia, CA 91355', 'USA', 'Q\u00b2 Solutions (Singapore)', 'Tan Tock Seng Hospital', 'Dept of Laboratory Medicine', 'Level 2, Podium Block', 'Tan Tock Seng Hospital', '11 Jalan Tan Tock Seng', 'Singapore 308433', 'DDL Diagnostic Laboratory B.V.', 'Fonteijnenburghlaan 7', 'Voorburg', 'Netherland', '19-OCT-2018', '119', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']\n\n###\n\n", "completion": "END"}